PortalPublikationenUpdate Breast Cancer 2018 (Part 1) - Primary Breast Cancer a...

Update Breast Cancer 2018 (Part 1) - Primary Breast Cancer and Biomarkers

Standard

Update Breast Cancer 2018 (Part 1) - Primary Breast Cancer and Biomarkers. / Taran, Florin-Andrei; Schneeweiss, Andreas; Lux, Michael P; Janni, Wolfgang; Hartkopf, Andreas D; Nabieva, Naiba; Overkamp, Friedrich; Kolberg, Hans-Christian; Hadji, Peyman; Tesch, Hans; Wöckel, Achim; Ettl, Johannes; Lüftner, Diana; Wallwiener, Markus; Müller, Volkmar; Beckmann, Matthias W; Belleville, Erik; Wallwiener, Diethelm; Brucker, Sara Y; Fasching, Peter A; Fehm, Tanja N; Schütz, Florian.

in: GEBURTSH FRAUENHEILK, Jahrgang 78, Nr. 3, 03.2018, S. 237-245.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Taran, F-A, Schneeweiss, A, Lux, MP, Janni, W, Hartkopf, AD, Nabieva, N, Overkamp, F, Kolberg, H-C, Hadji, P, Tesch, H, Wöckel, A, Ettl, J, Lüftner, D, Wallwiener, M, Müller, V, Beckmann, MW, Belleville, E, Wallwiener, D, Brucker, SY, Fasching, PA, Fehm, TN & Schütz, F 2018, 'Update Breast Cancer 2018 (Part 1) - Primary Breast Cancer and Biomarkers', GEBURTSH FRAUENHEILK, Jg. 78, Nr. 3, S. 237-245. https://doi.org/10.1055/s-0044-101613

APA

Taran, F-A., Schneeweiss, A., Lux, M. P., Janni, W., Hartkopf, A. D., Nabieva, N., Overkamp, F., Kolberg, H-C., Hadji, P., Tesch, H., Wöckel, A., Ettl, J., Lüftner, D., Wallwiener, M., Müller, V., Beckmann, M. W., Belleville, E., Wallwiener, D., Brucker, S. Y., ... Schütz, F. (2018). Update Breast Cancer 2018 (Part 1) - Primary Breast Cancer and Biomarkers. GEBURTSH FRAUENHEILK, 78(3), 237-245. https://doi.org/10.1055/s-0044-101613

Vancouver

Taran F-A, Schneeweiss A, Lux MP, Janni W, Hartkopf AD, Nabieva N et al. Update Breast Cancer 2018 (Part 1) - Primary Breast Cancer and Biomarkers. GEBURTSH FRAUENHEILK. 2018 Mär;78(3):237-245. https://doi.org/10.1055/s-0044-101613

Bibtex

@article{b3a4981351a44407a3810274092e008f,
title = "Update Breast Cancer 2018 (Part 1) - Primary Breast Cancer and Biomarkers",
abstract = "This summary provides an overview of how new therapies or new aspects of established therapies relate to the latest findings. Neoadjuvant therapy, local therapy, new aspects of systemic therapy, and prognostic and predictive factors are presented. In the neoadjuvant setting, the association between pathological complete response (pCR) and prognosis is still of interest as is the identification of new molecular predictors for new therapies such as CDK4/6 inhibitors. As regards surgical treatment, the target is still to reduce the aggressiveness of surgery. To achieve this, a better understanding particularly of ductal carcinoma in situ is required. With regard to systemic therapy, more data on the best combinations and therapy sequences for existing therapies is available. Finally, the use of prognostic and predictive factors may help to avoid overtreatment and ensure that patients only receive therapies which have been shown to be effective for their specific condition and have fewer side effects.",
keywords = "Journal Article",
author = "Florin-Andrei Taran and Andreas Schneeweiss and Lux, {Michael P} and Wolfgang Janni and Hartkopf, {Andreas D} and Naiba Nabieva and Friedrich Overkamp and Hans-Christian Kolberg and Peyman Hadji and Hans Tesch and Achim W{\"o}ckel and Johannes Ettl and Diana L{\"u}ftner and Markus Wallwiener and Volkmar M{\"u}ller and Beckmann, {Matthias W} and Erik Belleville and Diethelm Wallwiener and Brucker, {Sara Y} and Fasching, {Peter A} and Fehm, {Tanja N} and Florian Sch{\"u}tz",
year = "2018",
month = mar,
doi = "10.1055/s-0044-101613",
language = "English",
volume = "78",
pages = "237--245",
journal = "GEBURTSH FRAUENHEILK",
issn = "0016-5751",
publisher = "Georg Thieme Verlag KG",
number = "3",

}

RIS

TY - JOUR

T1 - Update Breast Cancer 2018 (Part 1) - Primary Breast Cancer and Biomarkers

AU - Taran, Florin-Andrei

AU - Schneeweiss, Andreas

AU - Lux, Michael P

AU - Janni, Wolfgang

AU - Hartkopf, Andreas D

AU - Nabieva, Naiba

AU - Overkamp, Friedrich

AU - Kolberg, Hans-Christian

AU - Hadji, Peyman

AU - Tesch, Hans

AU - Wöckel, Achim

AU - Ettl, Johannes

AU - Lüftner, Diana

AU - Wallwiener, Markus

AU - Müller, Volkmar

AU - Beckmann, Matthias W

AU - Belleville, Erik

AU - Wallwiener, Diethelm

AU - Brucker, Sara Y

AU - Fasching, Peter A

AU - Fehm, Tanja N

AU - Schütz, Florian

PY - 2018/3

Y1 - 2018/3

N2 - This summary provides an overview of how new therapies or new aspects of established therapies relate to the latest findings. Neoadjuvant therapy, local therapy, new aspects of systemic therapy, and prognostic and predictive factors are presented. In the neoadjuvant setting, the association between pathological complete response (pCR) and prognosis is still of interest as is the identification of new molecular predictors for new therapies such as CDK4/6 inhibitors. As regards surgical treatment, the target is still to reduce the aggressiveness of surgery. To achieve this, a better understanding particularly of ductal carcinoma in situ is required. With regard to systemic therapy, more data on the best combinations and therapy sequences for existing therapies is available. Finally, the use of prognostic and predictive factors may help to avoid overtreatment and ensure that patients only receive therapies which have been shown to be effective for their specific condition and have fewer side effects.

AB - This summary provides an overview of how new therapies or new aspects of established therapies relate to the latest findings. Neoadjuvant therapy, local therapy, new aspects of systemic therapy, and prognostic and predictive factors are presented. In the neoadjuvant setting, the association between pathological complete response (pCR) and prognosis is still of interest as is the identification of new molecular predictors for new therapies such as CDK4/6 inhibitors. As regards surgical treatment, the target is still to reduce the aggressiveness of surgery. To achieve this, a better understanding particularly of ductal carcinoma in situ is required. With regard to systemic therapy, more data on the best combinations and therapy sequences for existing therapies is available. Finally, the use of prognostic and predictive factors may help to avoid overtreatment and ensure that patients only receive therapies which have been shown to be effective for their specific condition and have fewer side effects.

KW - Journal Article

U2 - 10.1055/s-0044-101613

DO - 10.1055/s-0044-101613

M3 - SCORING: Journal article

C2 - 29576629

VL - 78

SP - 237

EP - 245

JO - GEBURTSH FRAUENHEILK

JF - GEBURTSH FRAUENHEILK

SN - 0016-5751

IS - 3

ER -